Abstract
Abstract
Background
The administration of 5-fluorouracil (5FU) in the treatment of gastrointestinal (GI) malignancies is associated with common side effects such as mucositis, diarrhoea, and myelosuppression, which are easily managed with supportive measures and dose adjustments. Cardiotoxicity and neurotoxicity are rare but reversible side effects of 5-FU and are treated with withdrawal of the drug and conservative measures. The presenting symptoms of 5-FU-induced leukoencephalopathy are often confusing and pose a diagnostic dilemma in routine clinical practice.
Methods
We report a series of five patients with GI malignancies who developed 5-FU-induced leukoencephalopathy.
Results
All (n = 5) had Naranjo scores of 6–7, predictive of 5-FU-related adverse effects, with clinical and radiological findings suggestive of 5-FU-induced encephalopathy as described in prior literature. The median time to onset of symptoms from initiation of 5FU was 3 days (range: 2–4 days). All patients improved after conservative management with complete neurological recovery.
Conclusion
Prompt recognition of this rare yet severe adverse effect of 5-FU-based chemotherapy aids early withdrawal of the offending agent (5-FU) and timely initiation of supportive measures and helps plan alternative oncological interventions.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Grem JL. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investig New Drugs. 2000;18:299–313. https://doi.org/10.1023/a:1006416410198.
2. Maheen Anwar SS, Mubarak F, Sajjad Z, Azeemuddin M. 5-FU induced acute toxic leukoencephalopathy: early recognition and reversibility on DWI-MRI. J Coll Physicians Surg Pak. 2014;24(Suppl 1):S8–10.
3. Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management. Curr Oncol Rep. 2016;18:35. https://doi.org/10.1007/s11912-016-0521-1.
4. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79:627–30. https://doi.org/10.1038/sj.bjc.6690098.
5. Fidai SS, Sharma AE, Johnson DN, Segal JP, Lastra RR. Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-fluorouracil toxicity. Autops Case Rep. 2018;8:e2018049. https://doi.org/10.4322/acr.2018.049.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献